$NKTR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEKTAR THERAPEUTICS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEKTAR THERAPEUTICS. Get notifications about new insider transactions in NEKTAR THERAPEUTICS for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 19 2021 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | S | 18.30 | 1,917 | 35,081 | 74,810 | 76.7 K to 74.8 K (-2.50 %) |
May 19 2021 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Sell | S | 18.30 | 6,085 | 111,356 | 207,107 | 213.2 K to 207.1 K (-2.85 %) |
May 14 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 13.80 | 8,000 | 110,400 | 24,000 | |
May 14 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 19.34 | 8,000 | 154,720 | 280,573 | 288.6 K to 280.6 K (-2.77 %) |
May 14 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 13.80 | 8,000 | 110,400 | 288,573 | 280.6 K to 288.6 K (+2.85 %) |
Apr 16 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 13.80 | 8,000 | 110,400 | 32,000 | |
Apr 16 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 18.98 | 8,000 | 151,840 | 280,573 | 288.6 K to 280.6 K (-2.77 %) |
Apr 16 2021 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 13.80 | 8,000 | 110,400 | 288,573 | 280.6 K to 288.6 K (+2.85 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 22.37 | 24,141 | 540,034 | 266,176 | 290.3 K to 266.2 K (-8.32 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | S | 22.37 | 2,173 | 48,610 | 76,727 | 78.9 K to 76.7 K (-2.75 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 22.37 | 11,705 | 261,841 | 164,552 | 176.3 K to 164.6 K (-6.64 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 22.37 | 11,495 | 257,143 | 447,198 | 458.7 K to 447.2 K (-2.51 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Sell | S | 22.37 | 15,358 | 343,558 | 213,192 | 228.6 K to 213.2 K (-6.72 %) |
Feb 18 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 22.37 | 7,977 | 178,445 | 258,996 | 267 K to 259 K (-2.99 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Option Exercise | M | 8.80 | 5,344 | 47,027 | 0 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | S | 19.45 | 5,344 | 103,941 | 78,900 | 84.2 K to 78.9 K (-6.34 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | M | 8.80 | 5,344 | 47,027 | 84,244 | 89.6 K to 84.2 K (-5.97 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 8.80 | 150,000 | 1,320,000 | 0 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 8.80 | 75,000 | 660,000 | 150,000 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 8.80 | 75,000 | 660,000 | 0 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 8.80 | 150,000 | 1,320,000 | 75,000 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 20.58 | 58,137 | 1,196,459 | 458,693 | 516.8 K to 458.7 K (-11.25 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 20.10 | 91,863 | 1,846,446 | 516,830 | 608.7 K to 516.8 K (-15.09 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 8.80 | 150,000 | 1,320,000 | 608,693 | 458.7 K to 608.7 K (+32.70 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 19.72 | 150,000 | 2,958,000 | 458,693 | 608.7 K to 458.7 K (-24.64 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 8.80 | 75,000 | 660,000 | 608,693 | 533.7 K to 608.7 K (+14.05 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 8.80 | 75,000 | 660,000 | 533,693 | 458.7 K to 533.7 K (+16.35 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 21.59 | 600 | 12,954 | 458,693 | 459.3 K to 458.7 K (-0.13 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 20.84 | 9,900 | 206,316 | 459,293 | 469.2 K to 459.3 K (-2.11 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 19.69 | 139,500 | 2,746,755 | 469,193 | 608.7 K to 469.2 K (-22.92 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 8.80 | 150,000 | 1,320,000 | 608,693 | 458.7 K to 608.7 K (+32.70 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | M | 8.80 | 50,000 | 440,000 | 0 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | M | 8.80 | 25,000 | 220,000 | 50,000 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | M | 8.80 | 25,000 | 220,000 | 0 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | M | 8.80 | 50,000 | 440,000 | 25,000 | |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.81 | 50,000 | 990,500 | 266,973 | 317 K to 267 K (-15.77 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Buy | M | 8.80 | 50,000 | 440,000 | 316,973 | 267 K to 317 K (+18.73 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.61 | 50,000 | 980,500 | 266,973 | 317 K to 267 K (-15.77 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Buy | M | 8.80 | 25,000 | 220,000 | 316,973 | 292 K to 317 K (+8.56 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Buy | M | 8.80 | 25,000 | 220,000 | 291,973 | 267 K to 292 K (+9.36 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 21.66 | 1,933 | 41,869 | 266,973 | 268.9 K to 267 K (-0.72 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 20.96 | 6,932 | 145,295 | 268,906 | 275.8 K to 268.9 K (-2.51 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.97 | 41,135 | 821,466 | 275,838 | 317 K to 275.8 K (-12.98 %) |
Feb 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Buy | M | 8.80 | 50,000 | 440,000 | 316,973 | 267 K to 317 K (+18.73 %) |
Jan 29 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | M | 8.80 | 37,500 | 330,000 | 0 | |
Jan 29 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | M | 8.80 | 37,500 | 330,000 | 0 | |
Jan 29 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 18.62 | 75,000 | 1,396,500 | 176,257 | 251.3 K to 176.3 K (-29.85 %) |
Jan 29 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Buy | M | 8.80 | 37,500 | 330,000 | 251,257 | 213.8 K to 251.3 K (+17.54 %) |
Jan 29 2021 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Buy | M | 8.80 | 37,500 | 330,000 | 213,757 | 176.3 K to 213.8 K (+21.28 %) |
Jan 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Gift | G | 0.00 | 51,500 | 0 | 51,500 | 0 to 51.5 K |
Jan 04 2021 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Gift | G | 0.00 | 51,500 | 0 | 185,850 | 237.4 K to 185.9 K (-21.70 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Option Exercise | A | 18.75 | 71,500 | 1,340,625 | 71,500 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Grant | A | 0.00 | 40,000 | 0 | 290,317 | 250.3 K to 290.3 K (+15.98 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Option Exercise | A | 18.75 | 51,000 | 956,250 | 51,000 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Grant | A | 0.00 | 28,550 | 0 | 78,900 | 50.4 K to 78.9 K (+56.70 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 18.75 | 28,600 | 536,250 | 28,600 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 16,000 | 0 | 176,257 | 160.3 K to 176.3 K (+9.98 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 18.75 | 190,650 | 3,574,688 | 190,650 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 106,650 | 0 | 458,693 | 352 K to 458.7 K (+30.29 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Option Exercise | A | 18.75 | 51,000 | 956,250 | 51,000 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Grant | A | 0.00 | 28,550 | 0 | 228,550 | 200 K to 228.6 K (+14.28 %) |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | A | 18.75 | 71,500 | 1,340,625 | 71,500 | |
Dec 22 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Grant | A | 0.00 | 40,000 | 0 | 266,973 | 227 K to 267 K (+17.62 %) |
Dec 17 2020 | NKTR | NEKTAR THERAPEUTIC ... | Myriam Curet | Director | Sell | S | 17.82 | 1,560 | 27,799 | 19,240 | 20.8 K to 19.2 K (-7.50 %) |
Nov 25 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 16.40 | 16,380 | 268,632 | 250,317 | 266.7 K to 250.3 K (-6.14 %) |
Sep 30 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 17.25 | 3,250 | 56,063 | 25,975 | 29.2 K to 26 K (-11.12 %) |
Sep 30 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 17.25 | 3,250 | 56,063 | 25,975 | 29.2 K to 26 K (-11.12 %) |
Sep 25 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 17.75 | 5,500 | 97,625 | 280,573 | 286.1 K to 280.6 K (-1.92 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Grant | A | 0.00 | 9,100 | 0 | 237,350 | 228.3 K to 237.4 K (+3.99 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Grant | A | 0.00 | 9,100 | 0 | 35,800 | 26.7 K to 35.8 K (+34.08 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Grant | A | 0.00 | 9,100 | 0 | 185,674 | 176.6 K to 185.7 K (+5.15 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | EASTHAM KARIN | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | EASTHAM KARIN | Director | Grant | A | 0.00 | 9,100 | 0 | 24,100 | 15 K to 24.1 K (+60.67 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Myriam Curet | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Myriam Curet | Director | Grant | A | 0.00 | 9,100 | 0 | 20,800 | 11.7 K to 20.8 K (+77.78 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Grant | A | 0.00 | 9,100 | 0 | 286,073 | 277 K to 286.1 K (+3.29 %) |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 9,100 | 0 | 29,225 | 20.1 K to 29.2 K (+45.22 %) |
Sep 21 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.96 | 2,000 | 39,920 | 235,249 | 237.2 K to 235.2 K (-0.84 %) |
Sep 21 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 19.74 | 2,250 | 44,415 | 20,125 | 22.4 K to 20.1 K (-10.06 %) |
Sep 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 9.24 | 8,000 | 73,920 | 0 | |
Sep 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 18.53 | 8,000 | 148,240 | 276,973 | 285 K to 277 K (-2.81 %) |
Sep 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 9.24 | 8,000 | 73,920 | 284,973 | 277 K to 285 K (+2.89 %) |
Sep 08 2020 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Option Exercise | M | 9.24 | 30,000 | 277,200 | 0 | |
Sep 08 2020 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | M | 9.24 | 30,000 | 277,200 | 228,250 | 198.3 K to 228.3 K (+15.13 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 19.67 | 26,200 | 515,354 | 296,315 | 322.5 K to 296.3 K (-8.12 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | S | 19.67 | 1,529 | 30,075 | 51,389 | 52.9 K to 51.4 K (-2.89 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 19.67 | 1,367 | 26,889 | 171,733 | 173.1 K to 171.7 K (-0.79 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 19.67 | 11,885 | 233,778 | 364,018 | 375.9 K to 364 K (-3.16 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.68 | 2,000 | 39,360 | 237,249 | 239.2 K to 237.2 K (-0.84 %) |
Aug 19 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 19.67 | 6,245 | 122,839 | 239,249 | 245.5 K to 239.2 K (-2.54 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 9.24 | 8,000 | 73,920 | 8,000 | |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 24.58 | 8,000 | 196,640 | 276,973 | 285 K to 277 K (-2.81 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 9.24 | 8,000 | 73,920 | 284,973 | 277 K to 285 K (+2.89 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 9.24 | 40,000 | 369,600 | 0 | |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 25.00 | 15,009 | 375,225 | 176,574 | 191.6 K to 176.6 K (-7.83 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 9.24 | 40,000 | 369,600 | 191,583 | 151.6 K to 191.6 K (+26.39 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 9.24 | 40,000 | 369,600 | 0 | |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 25.00 | 15,009 | 375,225 | 176,574 | 191.6 K to 176.6 K (-7.83 %) |
Jul 10 2020 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 9.24 | 40,000 | 369,600 | 191,583 | 151.6 K to 191.6 K (+26.39 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 22.51 | 4,558 | 102,601 | 322,515 | 327.1 K to 322.5 K (-1.39 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Wilson Mark Andrew | SVP & General Couns ... | Sell | S | 22.51 | 1,529 | 34,418 | 52,418 | 53.9 K to 52.4 K (-2.83 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 22.51 | 1,367 | 30,771 | 172,719 | 174.1 K to 172.7 K (-0.79 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 22.51 | 8,968 | 201,870 | 375,903 | 384.9 K to 375.9 K (-2.33 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 22.62 | 2,000 | 45,240 | 245,494 | 247.5 K to 245.5 K (-0.81 %) |
May 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 22.51 | 5,727 | 128,915 | 247,494 | 253.2 K to 247.5 K (-2.26 %) |
Apr 17 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 9.24 | 8,000 | 73,920 | 16,000 | |
Apr 17 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 19.02 | 197 | 3,747 | 276,973 | 277.2 K to 277 K (-0.07 %) |
Apr 17 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 18.36 | 7,803 | 143,263 | 277,170 | 285 K to 277.2 K (-2.74 %) |
Apr 17 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | M | 9.24 | 8,000 | 73,920 | 284,973 | 293 K to 285 K (-2.73 %) |
Mar 13 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 9.24 | 8,000 | 73,920 | 24,000 | |
Mar 13 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 17.41 | 1,200 | 20,892 | 276,973 | 278.2 K to 277 K (-0.43 %) |
Mar 13 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 16.68 | 6,800 | 113,424 | 278,173 | 285 K to 278.2 K (-2.39 %) |
Mar 13 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | M | 9.24 | 8,000 | 73,920 | 284,973 | 293 K to 285 K (-2.73 %) |
Feb 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 22.35 | 4,774 | 106,699 | 327,073 | 331.8 K to 327.1 K (-1.44 %) |
Feb 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 22.35 | 1,394 | 31,156 | 174,086 | 175.5 K to 174.1 K (-0.79 %) |
Feb 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 22.35 | 8,448 | 188,813 | 384,871 | 393.3 K to 384.9 K (-2.15 %) |
Feb 20 2020 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Sell | S | 22.35 | 5,938 | 132,714 | 253,221 | 259.2 K to 253.2 K (-2.29 %) |
Feb 14 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 9.24 | 8,000 | 73,920 | 32,000 | |
Feb 14 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 23.72 | 3,599 | 85,368 | 276,973 | 280.6 K to 277 K (-1.28 %) |
Feb 14 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 23.32 | 4,401 | 102,631 | 280,572 | 285 K to 280.6 K (-1.54 %) |
Feb 14 2020 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | M | 9.24 | 8,000 | 73,920 | 284,973 | 293 K to 285 K (-2.73 %) |
Feb 07 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | M | 7.21 | 37,500 | 270,375 | 0 | |
Feb 07 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 22.78 | 37,500 | 854,250 | 175,480 | 213 K to 175.5 K (-17.61 %) |
Feb 07 2020 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Buy | M | 7.21 | 37,500 | 270,375 | 212,980 | 175.5 K to 213 K (+21.37 %) |
Dec 20 2019 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Option Exercise | M | 9.24 | 10,000 | 92,400 | 30,000 | |
Dec 20 2019 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | M | 9.24 | 10,000 | 92,400 | 198,250 | 188.3 K to 198.3 K (+5.31 %) |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Myriam Curet | Director | Option Exercise | A | 21.79 | 23,400 | 509,886 | 23,400 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Myriam Curet | Director | Grant | A | 0.00 | 11,700 | 0 | 11,700 | 0 to 11.7 K |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Option Exercise | A | 21.79 | 20,100 | 437,979 | 20,100 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Option Exercise | A | 21.79 | 71,550 | 1,559,075 | 71,550 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Grant | A | 0.00 | 40,150 | 0 | 331,847 | 291.7 K to 331.8 K (+13.76 %) |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 21.79 | 11,800 | 257,122 | 11,800 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 21.79 | 26,600 | 579,614 | 26,600 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 14,900 | 0 | 175,480 | 160.6 K to 175.5 K (+9.28 %) |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 21.79 | 44,600 | 971,834 | 44,600 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 21.79 | 167,650 | 3,653,094 | 167,650 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 94,100 | 0 | 393,319 | 299.2 K to 393.3 K (+31.45 %) |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | A | 21.79 | 29,000 | 631,910 | 29,000 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Option Exercise | A | 21.79 | 71,550 | 1,559,075 | 71,550 | |
Dec 16 2019 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP, COO & CFO | Grant | A | 0.00 | 40,150 | 0 | 259,159 | 219 K to 259.2 K (+18.33 %) |
Dec 04 2019 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Option Exercise | A | 19.48 | 200,000 | 3,896,000 | 200,000 | |
Dec 04 2019 | NKTR | NEKTAR THERAPEUTIC ... | NORTHCOTT JOHN | SVP & Chief Commerc ... | Grant | A | 0.00 | 200,000 | 0 | 200,000 | 0 to 200 K |
Nov 20 2019 | NKTR | NEKTAR THERAPEUTIC ... | Zalevsky Jonathan | Chief R&D Officer | Sell | S | 17.97 | 3,960 | 71,161 | 291,697 | 295.7 K to 291.7 K (-1.34 %) |
Nov 20 2019 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 17.97 | 2,713 | 48,753 | 160,441 | 163.2 K to 160.4 K (-1.66 %) |
Nov 20 2019 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 17.97 | 13,556 | 243,601 | 299,219 | 312.8 K to 299.2 K (-4.33 %) |